pediatr
popul
respiratori
infect
common
caus
physician
visit
although
mani
respiratori
ill
selflimit
viral
infect
resolv
time
support
care
critic
identifi
caus
pathogen
earli
stage
diseas
order
implement
effect
antimicrobi
therapi
infect
control
last
year
diagnost
respiratori
infect
evolv
substanti
develop
novel
assay
avail
updat
test
newer
strain
pathogen
newer
laboratori
method
rapid
highli
sensit
specif
gradual
replac
convent
gold
standard
although
clinic
util
assay
still
evalu
articl
review
current
laboratori
method
avail
test
respiratori
pathogen
discuss
advantag
disadvantag
approach
acut
respiratori
tract
infect
one
lead
caus
childhood
morbid
mortal
worldwid
estim
global
respiratori
infect
respons
million
death
children
year
age
bryce
et
al
kalland
et
al
approxim
respiratori
infect
case
caus
viral
pathogen
influenza
b
respiratori
syncyti
viru
rsv
b
parainfluenza
viru
type
adenoviru
rhinoviru
human
metapneumoviru
hmpv
other
mahoni
nonspecif
clinic
present
respiratori
infect
pose
consider
challeng
differenti
diagnosi
pathogen
earli
accur
diagnosi
caus
pathogen
respiratori
infect
essenti
administ
appropri
antivir
antibacteri
therapi
initi
effect
infect
control
measur
reduc
length
hospit
stay
barenfang
et
al
byington
et
al
aker
et
al
last
decad
remark
improv
diagnosi
respiratori
pathogen
avail
molecular
pointofcar
poc
test
although
increas
number
laboratori
adopt
rapid
molecular
assay
convent
test
method
cultur
immunodiagnost
still
use
review
focus
current
laboratori
method
test
respiratori
pathogen
discuss
advantag
disadvantag
approach
electron
microscopi
em
one
oldest
direct
examin
method
implement
clinic
viral
diagnosi
studi
viral
ultrastructur
pathogenesi
develop
countri
roingeard
histor
em
play
instrument
role
identifi
novel
viral
strain
sever
outbreak
situat
coronaviru
associ
sever
acut
respiratori
syndrom
sar
outbreak
falsey
walsh
ksiazek
et
al
howev
despit
sever
advantag
use
em
limit
respiratori
viral
diagnosi
expens
labori
timeconsum
greater
turnaround
time
approxim
h
includ
specimen
prepar
often
insensit
compar
diagnost
method
goldsmith
miller
zhang
et
al
addit
em
requir
strict
control
experiment
condit
high
concentr
viral
particl
l
consider
technic
skill
expertis
accur
analysi
detect
virus
observ
cytopath
effect
hemadsorpt
cell
cultur
consid
gold
standard
diagnosi
respiratori
viral
pathogen
decad
virus
adenoviru
influenza
ab
rsv
human
parainfluenza
virus
common
respiratori
virus
isol
detect
cell
cultur
olsen
et
al
winn
koneman
tradit
tube
cultur
method
advantag
grow
wide
varieti
virus
includ
novel
unknown
virus
take
day
often
week
provid
result
year
modifi
cell
cultur
method
centrifug
enhanc
shellvial
method
reduc
turnaround
time
day
h
dilnessa
zelek
shellvial
cultur
use
combin
cell
line
allow
simultan
detect
multipl
respiratori
virus
compar
convent
cultur
similar
sensit
parainfluenza
vs
influenza
ab
vs
significantli
higher
sensit
rsv
vs
lasala
et
al
despit
advantag
mani
clinic
relev
virus
difficult
grow
cultur
rhinoviru
coronaviru
may
produc
variabl
result
ieven
goossen
hodinka
addit
multipl
freez
thaw
sampl
prior
test
reduc
viral
titer
thu
effect
growth
cultur
therefor
compar
molecular
test
tradit
tube
shellvial
cultur
method
labori
exhibit
higher
fals
neg
rate
longer
turnaround
time
make
viral
cultur
less
clinic
relev
leland
ginocchio
ginocchio
hematian
et
al
cultur
also
gold
standard
detect
atyp
bacteri
respiratori
pathogen
follow
identif
antimicrobi
suscept
test
variou
manual
autom
method
tenov
bacteri
cultur
also
often
insensit
especi
specimen
adequaci
determin
gram
stain
specimen
collect
antibiot
exposur
at
idsa
woodhead
et
al
harri
et
al
bacteri
cultur
also
labor
intens
requir
substanti
technic
expertis
typic
turnaround
time
h
antibiot
suscept
test
perform
therefor
consid
inadequ
optim
patient
care
guid
effect
antimicrobi
therapi
tenov
rapid
immunoassay
ria
deliv
test
result
less
min
usual
perform
poc
set
thu
allow
test
result
incorpor
clinic
decisionmak
algorithm
weinberg
walker
among
four
primari
ria
format
latex
agglutin
horizont
flow
devic
later
flow
devic
optic
immunoassay
lateralflow
immunoassay
lfia
versatil
popular
immunochromatograph
method
ria
rel
inexpens
easi
perform
waiv
statu
unit
state
accord
clinic
laboratori
improv
act
clia
guidelin
therebi
make
invalu
outpati
clinic
primari
care
emerg
low
resourc
set
ginocchio
current
commerci
avail
ria
mostli
limit
detect
influenza
viru
influenza
b
viru
rsv
numer
studi
reveal
ria
demonstr
overal
poor
sensit
influenza
rsv
howev
higher
median
specif
compar
cell
cultur
leland
ginocchio
ginocchio
pediatr
popul
commerci
avail
immunoassay
demonstr
high
sensit
detect
rsv
systemat
review
publish
studi
reveal
sensit
rsv
ria
rel
higher
children
adult
slinger
et
al
chartrand
et
al
higher
sensit
attribut
fact
pediatr
patient
often
shed
higher
titer
respiratori
virus
longer
time
compar
adult
englund
et
al
kawai
et
al
despit
overal
lower
sensit
ria
deem
valuabl
diagnost
tool
emerg
depart
significantli
decreas
length
stay
addit
ancillari
test
antibiot
prescript
children
test
posit
influenza
abans
et
al
blaschk
et
al
direct
fluoresc
antibodi
dfa
test
nasopharyng
wash
specimen
consid
rapid
reliabl
method
detect
respiratori
viral
infect
commerci
dfa
kit
demonstr
high
sensit
specif
multipl
respiratori
virus
hmpv
adenoviru
rsv
parainfluenza
virus
although
result
subject
requir
technic
expertis
accur
interpret
landri
ferguson
ohmsmith
et
al
rochol
et
al
aslanzadeh
et
al
vinh
et
al
high
specif
dfa
indic
test
use
reliabl
detect
method
especi
initi
day
ill
shown
shafik
et
al
rsv
children
pathogenspecif
antibodi
typic
appear
week
initi
infect
detect
serolog
test
serolog
test
success
identifi
antibodi
respiratori
pathogen
rsv
adenoviru
influenza
b
parainfluenza
viru
etc
detect
mix
infect
hospit
children
suffer
acut
respiratori
infect
except
infant
antibodi
respons
usual
undetect
hall
et
al
chkhaidz
et
al
howev
report
serolog
assay
significantli
less
sensit
detect
parainfluenza
viru
adenoviru
compar
molecular
method
rtpcr
kuyper
et
al
kuyper
et
al
found
rtpcr
detect
specimen
pediatr
patient
posit
least
one
respiratori
viru
detect
fluoresc
antibodi
assay
fa
fa
test
addit
rtpcr
use
epidemiolog
studi
increas
probabl
identifi
acut
viral
infect
use
accur
assess
respiratori
virus
influenza
children
sawatwong
et
al
feikin
et
al
zhang
et
al
bacteria
serolog
test
particularli
challeng
especi
identifi
atyp
bacteri
agent
mycoplasma
pneumonia
vari
sensit
specif
compar
pcr
serolog
test
limit
use
clinic
beersma
et
al
wellinghausen
et
al
clinic
util
serolog
test
limit
requir
acut
convalesc
sera
monitor
seroconvers
identifi
increas
antibodi
titer
loeffelholz
chonmaitre
addit
serolog
test
relev
identifi
frequent
recur
viral
infect
serum
igm
level
lower
due
repeat
exposur
vaccin
circul
virus
optim
viru
specif
igm
test
acutephas
serum
specimen
obtain
earli
cours
ill
dunn
wide
varieti
newer
nucleic
acid
amplif
test
naat
detect
respiratori
pathogen
commerci
avail
test
list
tabl
describ
accord
complex
pathogen
coverag
accuraci
respiratori
viru
detect
molecular
test
depend
specif
assay
chemistri
also
critic
affect
type
quantiti
qualiti
specimen
collect
dunn
sever
type
specimen
use
detect
respiratori
virus
includ
bronchoalveolar
lavag
bal
throat
swab
nasopharyng
np
wash
np
aspir
lung
aspir
np
swab
although
appropri
specimen
type
depend
specif
patient
popul
exampl
pediatr
patient
obtain
nasal
wash
nasal
aspir
technic
challeng
compar
np
swab
especi
sever
ill
children
poor
resourc
set
hammitt
et
al
observ
optim
test
result
specimen
collect
within
day
onset
symptom
ensur
sampl
high
concentr
viru
particl
viral
antigen
viral
nucleic
acid
transport
test
laboratori
refriger
condit
c
appropri
transport
media
test
perform
within
h
gri
smith
detect
respiratori
pathogen
naat
pcr
nucleic
acid
sequencebas
amplif
nasba
transcript
mediat
amplif
tma
strand
displac
amplif
sda
loopmedi
isotherm
amplif
lamp
roll
circl
amplif
rca
etc
gain
immens
popular
past
decad
larg
syndrom
panel
detect
multipl
pathogen
simultan
benefici
infect
control
time
treatment
decis
substanti
less
expens
detect
individu
pathogen
monoplex
realtim
rtpcr
reijan
et
al
schreckenberg
mcadam
multiplex
respiratori
panel
vari
term
complex
high
moder
waiv
throughput
pathogen
detect
abil
subtyp
instrument
batch
random
access
workflow
stepwis
integr
sampletoansw
eas
use
time
result
sever
hour
minut
caliendo
krunic
et
al
mahoni
et
al
studi
report
increas
diagnost
yield
vs
consider
higher
sensit
specif
assay
compar
convent
diagnost
method
dfa
viral
isol
immunoassay
reijan
et
al
gharabaghi
et
al
comparison
naatbas
molecular
method
highplex
syndrom
panel
demonstr
compar
perform
although
sensit
specif
might
vari
individu
target
sail
et
al
exampl
greater
specif
observ
target
except
enterovirusrhinoviru
overal
sensit
rang
nxtag
rpp
anyplex
ii
assay
evalu
detect
respiratori
pathogen
hospit
children
broton
et
al
syndrom
panel
also
detect
bacteri
infect
viralbacteri
coinfect
vital
develop
effect
treatment
plan
prevent
strategi
brealey
et
al
broton
et
al
howev
novel
pathogen
strain
flu
panel
test
often
fail
identifi
subtyp
requir
confirm
test
bryce
et
al
syndrom
respiratori
panel
high
sampl
throughput
usual
run
specimen
mostli
classifi
high
complex
assay
accord
clia
guidelin
indic
run
panel
requir
consider
knowledg
train
experi
fda
note
high
throughput
panel
ideal
batch
test
especi
outbreak
situat
respiratori
viral
season
sampl
volum
unusu
high
ginocchio
et
al
crawford
et
al
tang
et
al
despit
advantag
implement
high
throughput
panel
challeng
demand
sampl
prepar
process
result
interpret
procedur
turnaround
time
vari
approxim
h
beckmann
hirsch
moder
complex
sampletoansw
molecular
test
system
gain
immens
popular
last
year
eas
use
faster
turnaround
time
effici
workflow
current
unit
state
fdaclear
sampletoansw
test
system
includ
lowplex
target
assay
highplex
panel
detect
multipl
pathogen
pathogen
class
test
usual
low
moder
sampl
throughput
eg
samplesrun
faster
turnaround
time
compar
batch
high
throughput
multiplex
panel
popowitch
et
al
highplex
sampletoansw
panel
detect
pathogen
base
panel
size
qualit
assay
allow
random
access
ensur
test
perform
demand
reaction
occur
close
cassett
cartridg
therebi
minim
risk
contamin
poritz
et
al
popowitch
miller
compar
studi
evalu
perform
assay
report
agreement
differ
commerci
platform
greater
sensit
specif
case
babadi
et
al
howev
highplex
sampletoansw
test
demonstr
lower
sensit
certain
pathogen
adenoviru
influenza
influenza
b
viru
popowitch
et
al
crossreact
adenoviru
subtyp
also
report
assay
differenti
group
deem
clinic
import
routin
diagnosi
lin
et
al
gray
et
al
despit
short
turnaround
time
h
clinic
util
assay
question
sinc
statist
signific
reduct
antibiot
prescript
rate
mortal
observ
patient
test
posit
noninfluenza
viru
test
neg
vs
respect
green
et
al
case
reduct
length
hospit
stay
day
vs
day
durat
isol
h
vs
h
observ
roger
et
al
aker
et
al
primari
concern
highplex
sampletoansw
assay
high
cost
per
test
inabl
order
custom
target
panel
ramanan
et
al
multiplex
assay
verigen
rp
flex
panel
luminex
offer
flexibl
test
payment
option
allow
user
order
combin
target
individu
sampl
lowplex
integr
respiratori
test
system
typic
target
pathogen
per
assay
compar
studi
evalu
perform
assay
report
concord
differ
commerci
platform
greater
sensit
specif
case
duga
et
al
selvaraju
et
al
mcmullen
et
al
total
turnaround
time
per
sampl
assay
vari
h
number
sampl
test
standard
work
shift
depend
number
instrument
avail
test
laboratori
ling
et
al
smaller
panel
target
pathogen
run
independ
random
access
simultan
random
batch
could
viabl
option
control
laboratori
cost
therefor
consid
among
variou
test
option
recommend
addit
clinic
perform
assay
characterist
eas
use
panel
composit
total
turnaround
time
handson
time
cost
consid
implement
assay
variou
clinic
set
juretschko
et
al
nucleic
acid
amplif
base
poc
test
rel
new
realm
respiratori
viral
diagnosi
gener
contradict
opinion
regard
implement
clinic
util
molecular
poc
assay
extrem
short
turnaround
time
min
minim
handson
time
min
easili
oper
nonlaboratori
staff
member
therebi
make
suitabl
near
patient
implement
test
brendish
et
al
peter
et
al
ling
et
al
current
unit
state
fdaclear
commerci
poc
assay
limit
detect
influenza
ab
rsv
virus
except
filmarray
r
rp
ez
biofir
detect
target
fda
studi
evalu
clinic
perform
assay
report
high
sensit
specif
detect
influenza
ab
rsv
pediatr
adult
patient
bell
et
al
nie
et
al
popowitch
miller
gibson
et
al
ling
et
al
howev
studi
also
shown
clinic
perform
vari
sensit
significantli
low
influenza
b
therefor
result
interpret
caution
addit
confirmatori
test
consid
depend
clinic
circumst
jokela
et
al
busson
et
al
davi
et
al
molecular
poc
test
costli
prone
incorrect
result
contamin
assay
usual
perform
nonlaboratori
personnel
poor
train
failur
follow
manufactur
instruct
failur
perform
adequ
qualiti
control
might
affect
accuraci
result
azar
landri
current
evidencebas
studi
requir
understand
overal
clinic
util
molecular
poc
test
sinc
correl
observ
implement
test
reduct
antibiot
usag
hospit
length
stay
andrew
et
al
brendish
et
al
molecular
test
consider
improv
diagnosi
respiratori
pathogen
consid
new
gold
standard
although
test
gain
immens
popular
factor
patient
popul
adult
pediatr
immunocompromis
size
laboratori
purpos
test
routin
urgent
care
costbenefit
ratio
consid
implement
particular
assay
exampl
influenza
outbreak
two
nosocomi
case
identifi
memori
sloan
ketter
cancer
center
januari
despit
implement
appropri
infect
control
measur
five
case
identifi
day
later
januari
delay
report
posit
influenza
result
observ
laboratori
follow
routin
diagnost
algorithm
might
result
subsequ
case
nosocomi
infect
follow
outbreak
laboratori
implement
filmarray
r
rp
routin
diagnosi
xpert
r
xpress
flursv
rapid
molecular
poc
system
season
use
epidem
pandem
need
routin
test
urgent
care
complet
differ
situat
molecular
test
highli
sensit
specif
result
higher
pathogen
detect
therefor
physician
attend
clinician
evalu
test
result
initi
particular
cours
treatment
rapid
molecular
test
best
suit
routin
diagnosi
outbreak
situat
wherea
convent
method
cell
cultur
em
could
consid
identifi
novel
strain
pathogen
introduct
new
technolog
newer
assay
develop
respiratori
pathogen
exampl
use
np
swab
specimen
children
graf
et
al
demonstr
untarget
nextgener
sequencingbas
metagenom
mng
test
excel
agreement
multiplex
molecular
panel
detect
virus
either
target
panel
miss
due
highli
diverg
genom
sequenc
conclud
mng
use
accur
unbias
detect
expect
unexpect
pathogen
implement
mng
downstream
rapid
molecular
panel
test
proven
use
character
natur
hospitalassoci
transmiss
event
direct
control
strategi
pediatr
popul
outbreak
situat
grening
et
al
howev
diagnost
implement
ng
current
limit
incomplet
understand
analyt
perform
high
cost
system
complex
sequenc
data
analysi
futur
research
necessari
focu
demonstr
clinic
util
new
upcom
assay
variou
patient
popul
resourc
limit
set
